Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.72 |
| ▸ | HTR2B | P41595 | 3/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412479 | 1.00 | HTR2A (0.72) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| SCHEMBL2421761 | 1.00 | HTR2A (0.72) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| SCHEMBL5706525 | 1.00 | HTR2A (0.72) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| SCHEMBL19040919 | 0.85 | HTR2A (0.71) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| SCHEMBL2659237 | 0.85 | HTR2A (0.77) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| Nordexfenfluramine SCHEMBL4668266 | 0.84 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| Nordexfenfluramine SCHEMBL44927 | 0.84 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| Nordexfenfluramine SCHEMBL895637 | 0.84 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| Nordexfenfluramine SCHEMBL30081489 | 0.84 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C | |
| SCHEMBL18888417 | 0.84 | HTR2A (0.74) | HTR2AHTR2BHTR2CSIGMAR1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349950-B1 | A PROCESS FOR THE PREPARATION OF 1-(3-TRIFLUOROMETHYLPHENYL)-PROPAN-2-OL ENANTIOMERS | FIDIA FARMACEUTICI (IT) | 2006-11-02 | — | — | EP | claimed |
| US-6987205-B2 | Process for the preparation of 1-(3-trifluoromehylphenyl)-propan-2-ol enantiomers | FIDIA FARMACEUTICI S.P.A. (IT) | 2006-01-17 | — | — | US | claimed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-3887481-A1 | A METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS | Zogenix International Limited (GB) | 2021-10-06 | — | — | EP | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| WO-2020112460-A1 | A METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
| EP-1349950-B1 | A PROCESS FOR THE PREPARATION OF 1-(3-TRIFLUOROMETHYLPHENYL)-PROPAN-2-OL ENANTIOMERS | FIDIA FARMACEUTICI (IT) | 2006-11-02 | — | — | EP | disclosed |
| US-6987205-B2 | Process for the preparation of 1-(3-trifluoromehylphenyl)-propan-2-ol enantiomers | FIDIA FARMACEUTICI S.P.A. (IT) | 2006-01-17 | — | — | US | disclosed |
| US-20050176119-A1 | Process for the preparation of 1-(3-trifluoromehylphenyl) -propan-2-ol enantiomers | FIDIA FARMACEUTICI S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
| EP-1349950-A1 | A PROCESS FOR THE PREPARATION OF 1-(3-TRIFLUOROMETHYLPHENYL)-PROPAN-2-OL ENANTIOMERS | Fidia Farmaceutici S.p.A. (IT) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055724-A1 | A PROCESS FOR THE PREPARATION OF 1-(3-TRIFLUOROMETHYLPHENYL)-PROPAN-2-OL ENANTIOMERS | FIDIA RESEARCH SUD S.P.A. (IT) | 2002-07-18 | — | — | WO | disclosed |
| EP-0882700-A2 | Process for the production of the dexfenfluramine hydrochloride | ALFA CHEMICALS ITALIANA S.p.A. (IT) | 1998-12-09 | — | — | EP | disclosed |
| EP-0875498-A2 | Process for the production of the isomers (R) and (S)-Alpha-methyl-3-(trifluoromethyl)benzeneethanamine | Alfa Chemicals Italiana S.r.l. (IT) | 1998-11-04 | — | — | EP | disclosed |
| US-5808156-A | Process for the production of the isomers (R) and (S)-α-methyl-3(trifluoromethyl)benzeneethanamine | ALFA CHEMICALS ITALIANA S.P.A. (IT) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176119-A1 | Process for the preparation of 1-(3-trifluoromehylphenyl) -propan-2-ol enantiomers | LPL, PNLIP, LIPE | HTR2A 1675/4885HTR2B 2739/4885HTR2C 2424/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HTR2A 3716/4885HTR2B 3566/4885HTR2C 2712/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HTR2A 3808/4885HTR2B 3591/4885HTR2C 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.